Latest news with #MedTech
Business Insider
3 days ago
- Business
- Business Insider
Beta Bionics initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst David Roman initiated coverage of Beta Bionics (BBNX) with a Neutral rating and $16 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Beta Bionics technology is well suited for a targeted segment of the Type 1 market, the analyst tells investors in a research note. Goldman Sachs added however that while the company's near-term growth should outpace Diabetes peers and SMID cap MedTech, consensus estimates seem to largely capture the opportunity over the next several years, with valuation reflecting both that level of growth and the need to raise capital down the road to achieve cash flow breakeven. Confident Investing Starts Here:
Yahoo
4 days ago
- Business
- Yahoo
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical devices, imaging technologies, diagnostics, AI/data analytics and digital health. MedTech, AI & Digital Health ConferenceDates: June 3-4, 2025Location: O'Melveny Conference Center, San Francisco, CAConference registration: The MedInvest Conference is a leading conference series in Healthcare and Life Sciences. MedInvest hosts semiannual conferences in Biotech and Pharma and in MedTech, AI, and Digital Health. To learn more or to register, please visit their website: About NeuroOne NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit IR ContactMZ Group – MZ North AmericaNMTC@ in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
POMPANO BEACH, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company's CEO, will participate in a fireside chat and will be available for one-on-one meetings. For conference attendees wishing to schedule a meeting, please contact Noah Agron, VP Corporate Finance and Strategy, at nagron@ Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Contact BioStem Technologies, Inc.:Phone: 954-380-8342Website: info@ @BSEM_TechFacebook: BioStemTechnologies Investor Relations:Adam HoldsworthE-Mail: adam@ 917-497-9287Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
5 days ago
- Business
- Associated Press
ROTH Announces the Addition of Kyle Bauser, Ph.D. to its Healthcare Research Team
NEWPORT BEACH, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Roth Capital Partners ('ROTH'), today announced Kyle Bauser, Ph.D., as Managing Director, Senior Research Analyst. Dr. Bauser has joined the firm's healthcare research team, covering the medical technology sector. He has over a decade of MedTech experience across equity research and industry. Dr. Bauser began his career in MedTech equity research over 12 years ago at Piper Sandler. He later worked in marketing and corporate development at Vascular Solutions before returning to research at Dougherty & Co, where he became Managing Director and Co-Head of Equity Capital Markets. His research primarily focuses on small- to mid-cap and underfollowed companies with novel technologies. He studied Mathematical Economics and Pre-Med at Colorado College as an undergraduate and earned a Ph.D. in Economics from the City University of New York Graduate Center. Jeff Martin, CFA, Co-Director of Research & Senior Research Analyst at ROTH, commented, 'I'm pleased to welcome Kyle to our healthcare research team. I am confident his strong research background and understanding of equity markets in MedTech will serve our clients well.' 'We are committed to expanding our research department across industries and market caps', said Sagar Sheth, CEO of ROTH. 'I'm confident that Kyle's expertise will provide valuable insights for our clients and help expand our healthcare practice.' Dr. Bauser noted, 'I am thrilled to be joining the impressive ROTH platform, which has a full suite of offerings dedicated to small-cap growth companies. I look forward to collaborating with the team and utilizing my diverse set of experiences to identify unique MedTech opportunities for our clients.' Since 2010, ROTH has been involved in over 600 transactions for its healthcare clients, with a total transaction value of over $25 Billion. (Source: ROTH 05.21.25) About ROTH: ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information on Roth, please visit Investor Contact ROTH Isabel Mattson-Pain Managing Director, Chief Marketing Officer [email protected] | 949.720.7117 ROTH – Member FINRA/SIPC – Wire Service Contact: IBN Austin, Texas 512.354.7000 Office [email protected]
New Indian Express
6 days ago
- Business
- New Indian Express
Quadria's oversubscribed fund: What it signals for Asia's healthcare industry
'It reflects the strong global investor confidence in the transformational opportunity within Asian healthcare, where social impact and financial performance go hand in hand,' confirms Abrar Mir, co-founder and managing partner at Quadria Capital. Quadria Capital said in a statement on Tuesday that Fund III drew support from prominent sovereign wealth funds, asset managers, and strategic corporates across North America and Europe. It also secured new commitments from globally recognised institutional investors, with notable participation from leading institutions in the GCC—including Saudi Arabia, the UAE, and Bahrain. In India, the Fund attracted new capital from major banks, insurance companies, and family offices. Additionally, robust re-up commitments from impact investors reaffirm Quadria's dedication to building scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Asian Healthcare Scenario Currently Asia's healthcare market is estimated to be $5 trillion, and the healthcare industry is reportedly at a pivotal inflection point and will remain a focal area into 2025. "In India, particularly, we're seeing significant investment interest in single-specialty hospitals, diagnostics, medical devices, and pharmaceutical manufacturing—including active pharma ingredients (APIs) and contract (drug) development and manufacturing (CDM). These segments are poised for growth due to increasing healthcare consumption, cost-efficiency initiatives, and deeper technology integration," says Dr Amit Verma, co-founder and managing partner, Quadria Capital. Healthcare growth funds like Quadria's typically provide the industry with strategic guidance and operational support to help scale their businesses and achieve market leadership. Quadria claims that nearly 40% of Fund III is already deployed. Its current investments include Aragen Life Sciences (a global CRDMO serving 400+ pharmaceutical clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected shortly, it says. India Impact India is rapidly emerging as a strategic hub for global pharmaceutical and MedTech manufacturing as supply chains diversify, especially with the China plus strategy. While the per capita healthcare spending in India remains low at just $74—far below regional peers like Thailand (US$364) and Malaysia (US$487)—with nearly 50% of healthcare costs still paid out-of-pocket, the healthcare focused funds can catalyse Indian healthcare innovation by strategically investing in high-growth areas such as specialised care and pharmaceutical manufacturing, aiming to create scalable, affordable healthcare solutions for over a billion people.
